GLP-1 drugs currently being tested in China target complications associated with obesity such as heart disease, fatty liver ...

A UCSF analysis has found that the newer generation of much more effective diabetes medications are reaching only a fraction ...

Glucagon receptors, found in hepatocytes and renal cells, may provide further advantages, perhaps lowering the incidence of metabolic liver diseases and diabetic kidney disease.

On readmission, in January, 1965, no new physical findings were evident, and it was not known whether the zinc glucagon was inactive or the worsening condition was due to progression of the disease.